SQ Innovation's Lasix ONYU Subcutaneous Heart Failure Trial Results to Be Presented at Heart Failure 2026

Key Takeaways

• SUBCUT HF II represents the first full-scale outcomes trial of subcutaneous furosemide for at-home heart failure treatment
• Results could transform heart failure care by enabling patients to self-administer diuretic therapy at home instead of hospital visits
• Trial data will be presented May 9th at the Heart Failure Association congress in Barcelona

---

SQ Innovation announced that results from its pivotal SUBCUT HF II trial evaluating Lasix ONYU for at-home treatment of heart failure-associated edema will be presented at Heart Failure 2026 on May 9th in Barcelona.

The SUBCUT HF II trial marks a significant milestone as the first comprehensive outcomes study of subcutaneous furosemide administration for heart failure patients. Lasix ONYU enables patients to self-administer diuretic therapy at home, potentially reducing hospitalizations and improving quality of life for the millions affected by heart failure worldwide.

Revolutionary Approach to Heart Failure Management

Traditional heart failure treatment requires patients to visit healthcare facilities for intravenous diuretic administration when experiencing fluid retention episodes. SQ Innovation’s subcutaneous delivery system could fundamentally change this paradigm by allowing patients to manage their condition independently at home.

Heart failure affects over 64 million people globally, with edema being one of the most common and debilitating symptoms. Current treatment options often require emergency department visits or hospital admissions for diuretic therapy, creating significant healthcare system burden and patient inconvenience.

IntelligenceRegulatory Impact▾

EMA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Clinical Trial Significance

The SUBCUT HF II trial’s full-scale design provides robust data on both efficacy and safety outcomes for at-home subcutaneous furosemide therapy. This represents a critical advancement from earlier pilot studies, offering comprehensive evidence for regulatory review and clinical adoption.

Results presentation at the Heart Failure Association’s annual congress underscores the international significance of this research. The European Society of Cardiology’s Heart Failure Association congress is considered the premier venue for groundbreaking heart failure research.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Future Implications

If positive, these results could position Lasix ONYU as a game-changing therapy in the heart failure treatment landscape. The ability to provide effective diuretic therapy outside hospital settings addresses a major unmet need in cardiovascular medicine.

The timing of this announcement, just days before the congress presentation, suggests SQ Innovation is confident in the trial outcomes and preparing for potential regulatory submissions and commercialization discussions.

---

Frequently Asked Questions

What does this mean for heart failure patients?

If successful, Lasix ONYU could allow heart failure patients to treat fluid retention episodes at home using subcutaneous injections, potentially avoiding hospital visits and improving their quality of life.

When will Lasix ONYU be available to patients?

The timeline depends on the trial results being presented May 9th. If positive, SQ Innovation would likely pursue regulatory approval, which typically takes 6-12 months for breakthrough therapies.

How does subcutaneous furosemide compare to current treatments?

Current heart failure treatments often require intravenous administration in clinical settings. Subcutaneous delivery would offer the convenience of at-home administration while potentially maintaining similar efficacy to IV therapy.

Related coverage

• Karyopharm's Selinexor Plus Ruxolitinib SENTRY Trial Data to be Presented at EHA 2026
• KRX IR Reference : Executive Summary Plan for SCD NDR (ENG, Jun 2026)
• EMEA 2026 Life Sciences Report: Key Market Shifts for Pharma BD and Investors